HCPLive

Mindfulness-Based Cognitive Therapy Improves Posttraumatic Stress Disorder

FRIDAY, April 26 (HealthDay News) -- Mindfulness-based cognitive therapy (MBCT) can provide significant and clinically meaningful improvement in posttraumatic stress disorder (PTSD) symptoms, according to a pilot study published online April 17 in Depression and Anxiety.

Anthony P. King, PhD, from the University of Michigan, in Ann Arbor, and colleagues enrolled consecutive patients seeking treatment for chronic PTSD at a VA outpatient clinic in either eight-week MBCT groups, modified for PTSD (four groups; 20 participants), or brief treatment-as-usual (TAU) comparison group interventions (three groups; 17 participants). Clinician administered PTSD scales (CAPS) were performed on all patients as pre- and post-therapy psychological assessments. Self-report measures (PTSD diagnostic scale [PDS] and posttraumatic cognitions inventory [PTCI]) were administered in the MBCT group.

The researchers observed significant improvement in PTSD in the MBCT group but not the TAU group. There was a significant Condition × Time interaction. The 15 participants who completed MBCT showed good compliance with assigned homework exercises as well as significant and clinically meaningful improvement in PTSD symptom severity in CAPS and PDS (particularly in avoidance/numbing symptoms) and reduced PTSD-relevant cognitions in PTCI (self-blame).

"These data suggest group MBCT as an acceptable brief intervention/adjunctive therapy for combat PTSD, with potential for reducing avoidance symptom cluster and PTSD cognitions," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Stem cell transplants significantly reduce multiple sclerosis disease activity better than mitoxantrone, according to research published in Neurology.
Having a challenging job may help people live longer after developing frontotemporal dementia, according to a small study published online April 22 in Neurology.
Fred Lublin, MD, and Patricia K. Coyle, MD, describe the approval and use of alemtuzumab for patients with multiple sclerosis.
Fred Lublin, MD, and Patricia K. Coyle, MD, discuss issues surrounding insurance coverage of therapies for multiple sclerosis.
$vAR$